News
NRIX
12.36
-10.11%
-1.39
Weekly Report: what happened at NRIX last week (0415-0419)?
Weekly Report · 3d ago
Analysts’ Top Healthcare Picks: Evolent Health (EVH), Nurix Therapeutics (NRIX)
TipRanks · 04/17 11:21
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Nurix Therapeutics, Inc. Announced the closing of its underwritten public offering of 11,916,667 shares of its common stock. Nurix sold to certain investors pre-funded warrants to purchase 1,500,000 shares. The net proceeds from the offering were approximately $188.6 million.
Barchart · 04/16 17:21
Weekly Report: what happened at NRIX last week (0408-0412)?
Weekly Report · 04/15 12:01
Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
NASDAQ · 04/15 11:31
Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies
Nurix Therapeutics raises $175 million in an upsized offering after a 168% stock return in the past six months. The biotech company is developing protein degraders, with NX-2127 and NX-5948, targeting B-cell malignancies. Nurix's protein de graders are focused on BTK, a target also addressed by Johnson & Johnson's popular drug Imbruvica.
Seeking Alpha · 04/15 11:30
Nurix Therapeutics (NASDAQ:NRIX) Climbs Higher After Beating Expectations
TipRanks · 04/15 11:11
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
JPMorgan Chase & Co. Shares dipped 5.1% to $185.49 following first-quarter earnings on Friday. PaxMedica, Inc. Shares jumped 143% after the company reported better-than-expected results on Thursday. Rent the Runway shares jumped 162% on Thursday after reporting mixed results.
Benzinga · 04/12 18:47
BUZZ-U.S. STOCKS ON THE MOVE-Virco, Argan, State Street
Wall Street's main stock indexes fell on Friday. The Dow Jones Industrial Average was down 1.48% and the S&P 500 and Nasdaq Composite were also down. Some big banks dipped after reporting dour quarterly results. The top three growth stocks and chipmakers receded. Virco, Argan and State Street were up.
Reuters · 04/12 18:20
BUZZ-U.S. STOCKS ON THE MOVE-Exxon, Oil stocks, Nextplat
The blue-chip Dow and the S&P 500 were on track for weekly losses on Friday. Most megacap growth stocks and chipmakers retreated, while some big banks fell after reporting dour quarterly earnings. The Dow Jones Industrial Average was down 0.84% at 38,136.43 and the Nasdaq Composite was down 1.08%.
Reuters · 04/12 16:23
Top 10 stocks with upwards and downwards daily percentage change - Piper Sandler
Piper Sandler published the top 10 stocks with upwards and downwards daily percentage change as of Thursday. The S&P 500 (SP500) is vulnerable to a possible 5-10% pullback in upcoming weeks or months, analysts say. High-interest rates, inflation, and mediocre breadth are making the market vulnerable to pullback, Piper Sandler says.
Seeking Alpha · 04/12 15:34
BUZZ-U.S. STOCKS ON THE MOVE-Netflix, Citigroup, silver miners
Dow e-minis were down 0.87% in early trading on Friday. Wall Street's main stock indexes on track for a lower open. Netflix, silver miners and chipmakers rise. Citigroup and JPMorgan Chase dip after dour quarterly results. The top two NYSE percentage gainers were Via Optronics and silver miners.
Reuters · 04/12 13:31
Applied Digital Reports Downbeat Results, Joins Nurix Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Applied Digital Corporation shares fell sharply in today’s pre-market trading after the company reported worse-than-expected third-quarter financial results. The Dow futures fell over 50 points on Friday. U.S. Stock futures were lower in today's trading session.
Benzinga · 04/12 12:04
BUZZ-Nurix Therapeutics drops after upsized $175 mln stock offering
Nurix Therapeutics Inc's shares down 5.3% at $16.30 premarket after upsized $175 mln stock offering. Biopharma firm Nurix announced 11.7 mln shares to be sold at $15 each. Nurix shares closed up 27% last week.
Reuters · 04/12 11:36
NURIX THERAPEUTICS SHARES DOWN 8.4% PREMARKET AFTER CO ANNOUNCES PRICING OF UPSIZED PUBLIC OFFERING
Reuters · 04/12 10:56
Biggest stock movers today: NRIX and APLD
Nurix Therapeutics, Inc. (NRIX) stock fell over 8% after pricing an upsized public offering. Shares of Applied Digital slumped 10% following disappointing FQ3 results. NRIX and APLD were the biggest stock movers on Friday.
Seeking Alpha · 04/12 09:41
Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
Shares of NextPlat Corp rose sharply in today’s pre-market trading. The company reported consolidated 2023 revenues of $37.8 million, up 222% year over year. Rent the Runway shares jumped 162% on Thursday after the company reported mixed fourth-quarter financial results.
Benzinga · 04/12 09:32
Nurix Therapeutics prices upsized stock offering to raise $175.0 million
Healthcare Nurix Therapeutics prices upsized stock offering to raise $175.0 million. Shares were down 6.33% in pre-market trade on Friday. Nurix is offering 10.17 million shares of its common stock at $15.00 per share.
Seeking Alpha · 04/12 08:32
Nurix Therapeutics Prices Upsized $175M Public Offering Of 10,166,667 Common Shares At $15/Share
Nurix Therapeutics, Inc. Announces upsized underwritten public offering of 10,166,667 shares of its common stock. Nurix also offering to certain investors pre-funded warrants to purchase up to 1,500,000 shares of common stock in lieu of stock.
Benzinga · 04/12 06:50
More
Webull provides a variety of real-time NRIX stock news. You can receive the latest news about Nurix Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About NRIX
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).